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SUMMARY
The cell-mediated immune response (CMI) to E6 and E4 fusion proteins of
human papillomavirus type 16 (HPV-16), E6 fusion protein of HPV-18, and to
control proteins similarly produced, was analysed in 29 patients with cervical
intraepithelial neoplasia (CIN) and in 15 age-matched laboratory personnel using
a lymphocyte proliferation assay (LPA).
Compared to controls without any added proteins, a positive response
(stimulation index > 2-0) to the highly purified E6 control protein was found in
only one patient. Positive responses to the E4 control protein which contained ,-
galactosidase were noted in three patients and two controls.
With control proteins as baseline, the lymphocytes from nine patients (28%)
and three laboratory personnel (20%) responded to at least one HPV fusion
protein after 7 days in culture. Stimulation indices were low in both groups with
a range of 2 06-4-69 and the difference in incidence of positive responses between
the groups is not significant. Proliferative responses to HPV-1 and HPV-2 virion
antigens were noted in 6/23 (26%) of the patients and 2/15 (18%) of the other
group.
No correlation between responsiveness and degree of dysplasia or presence of
koilocytes was found in the patient group. The relevance of the low proliferative
responses is discussed.
INTRODUCTION
A role for human papilloma virus (HPV) in the induction of cervical cancer was
first suggested by zur Hausen and his colleagues in 1975 (1). Specific
papillomavirus DNA sequences, particularly of HPV-16 and HPV-18, have been
present in the vast majority of premalignant and malignant cervical tumours
analysed (2). It is possible that HPV may act as an 'initiator' of malignancy as
appears to be the case in the transformation of alimentary papillomas to
carcinomas by bovine papillomavirus type 4 (3), or as a 'promoter' following
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initiation by some other event such as infection with herpes simplex virus or the
carcinogenic effects of smoking (4).
It is becoming increasingly evident, however, that the immune status of the
patient is an important element in the outcome of HPV infection. The rare disease
of epidermodysplasia verruciformis, in which there is an underlying defect of cell-
mediated immunity (CMI) (5), is associated with widespread and persistent flat
warts and plaque-like lesions which frequently progress to malignancy especially
in sun-exposed areas (6). Similarly patients, immunosuppressed therapeutically
after renal allograft transplantation, develop multiple persistent warts resistant to
treatment, some of which may progress to skin carcinomas (6-8). An increase in
cervical intraepithelial neoplasia (CIN) in renal allograft recipients and in patients
immunosuppressed as a result of underlying malignancy (9, 10) has been
recognized for some time, and in some cases at leasf these lesions have been shown
to be HPV-associated (11).
In vitro assays of specific systemic cellular responses to HPV infection were
described more than 10 years ago (12-14) from which it was evident that, in
patients whose warts regressed spontaneously, a specific T-cell mediated response
could be observed. The responses were, however, low and relatively short-lived. In
an attempt to investigate the immune response to HPV infection in patients with
CIN, we described a lymphoproliferation assay (LPA) using several PV antigens
including SDS-disrupted and glycine-extracted bovine papillomavirus type 1
(BPV-1), HPV-1 and HPV-2 virus preparations (15). No correlation was found
between positive responses and the presence in cervical biopsies of koilocytes
(pathognomonic for HPV infection) nor between positive responses and the degree
of dysplasia present. However, positive T-cell responses did correspond with a
history of past or present hand and/or foot warts. There exists the possibility that
papilloma antigens prepared from skin warts, even when treated to reveal group
specific antigens, do not contain the correct epitopes to screen for T lymphocytes
responding to the HPV types found in the cervix.
It has recently been shown that cervical carcinomas and cultured cell lines of
cervical carcinoma origin, although negative for virion antigens, do contain early
proteins, particularly coded by the E6/E7 segment of the HPV genome (16-18).
Fusion proteins containing E6 from HPV-16 and HPV-18 have been produced
following the insertion of the entire E6 open reading frame (ORF) into pAS
plasmid vector (19). In addition, fl-galactosidase fusion proteins have been made
containing the HPV- 16 E4 ORF. Thus it is now possible to look for memory T cells
recognizing some early antigens of HPV types relevant to cervical infections. The
results of such a study are given in this paper.
MATERIALS AND METHODS
Subjects
Venous blood, totalling 10-20 ml was collected in preservative-free heparin
from 29 patients (with a mean age of 31-6+770 years) attending the Lothian
Colposcopy Clinic for investigation of 'suspicious' or abnormal cervical smears.
Colposcopically-directed cervical biopsies were taken at the same time for
histopathology. Blood was also obtained from 15 healthy female members of staff
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(mean age 30-1 + 7-6 years). All subjects were asked if they had skin warts or has t
had them in the past.
HPV fusion proteins
E6 proteins of IIPV-16 and HPV-18 were synthesized in Escherichia coli
AR120 using pAS constructs (20) and purified by superose 12 fast protein liquid
chromatography as described by Banks and co-workers (19). A control protein
preparation from E. coli containing no HPV sequences was similarly prepared.
HPV- 16 E4-fl-galactosidase fusion protein was expressed in E. coli as follows: a 2-6
kb Bal I fragment from HPV-16 containing the C-terminal portion of E4, but
lacking the putative N-terminal portion, had Bgl II linkers attached, was cut with
Bgl II and ligated into Bam HI/Bgl II cut pUR288 (21). Ampicillin-resistant
colonies were screened for fusion protein on SDS PAGE following induction with
100 ,tg/ml isopropyl-,/-D-thiogalactoside. E4 /8-galactosidase fusion protein and
control f8-galactosidase were purified by gel filtration on sepharose CL-4B
(Pharmacia). The fusion proteins were suspended in a buffer of 0-02 % SDS, 50 mM
Tris-HCl pH 7-5 and 5% glycerol at protein concentrations of 25,tg/ml. They
were aliquoted and stored at -70 °C and, immediately prior to use, diluted from
10-1 to 10-4 in cell culture medium.
Lymphocyte proliferation assay
The assay was carried out as described by Cubie and Norval (15) except that the
culture period was 7 instead of 8 days which gave more consistent results between
replicate wells. Briefly, washed peripheral blood mononuclear cells (PBM) were
suspended in culture medium (RPMI- 1640) containing 15% autologous plasma
and seeded into wells of microtitre plates in quintuplicate (2 x 105 cells/well). Five
microlitres of antigen was added to each well and the plates incubated in a
humidified atmosphere of 5% CO2. The day before harvesting 0-75 /sCi [3H]methyl
thymidine was added to each well. Harvesting and counting were carried out as
previously described. Stimulation indices (SI) were calculated from the ratio:
cpm of cultures in the presence of control or HPV protein
cpm of cultures in the presence of culture medium or control protein'
SI greater than two were considered positive.
Controls of the test system were included as follows: the mitogen, concanavalin
A, was added to quintuplicate wells in all assays, a virion antigen preparation of
purified HPV-2 or HPV-1 (15) was included whenever sufficient lymphocytes were
available, and occasionally a glycine-extract of Vero cells infected with herpes
simplex virus type 1 (HSV-1) (22).
RESULTS
The lymphoproliferative responses to control proteins of HPV-16/18 E6 and
HPV-16 E4-,l galactosidase were assessed against a baseline of culture medium as
mock antigen. Only one patient (out of 29) and none of the laboratory controls
(out of 15) responsed to the control E6 protein after 7 days in culture. No positive
responses were noted after 3 or 5 days in culture in those specimens with sufficient
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Table 1. Patients with CIN and laboratory personnel with positive
lymphoproliferative responses to control proteins of HPV-16/18 and HPV-16 E4
Lymphoproliferative response to
Culture medium Control protein
Control Patient Days in , , A
protein number culture x cpm S.E. x cpm S.E. SI
E6 P31 7 1305 298 3087 748 2-37
E4 P12 7 328 8 835 111 2-55
P31 7 1305 298 5546 608 4-25
P33 7 270 35 601 67 2-23
C5 7 706 113 1432 165 2 03
C13 3 261 6 541 36 2-07
C13 5 540 51 1255 128 2-32
P, patient; C, laboratory personnel; x cpm, mean counts per min; S.E., standard error; SI,
stimulation index.
PBM for testing at earlier time points. Three patients and two laboratory controls
responded to the control E4-,/ galactosidase protein (Table 1). SI ranged from 2-03
to 4 25 and were observed after 7 days in culture in patients, and at differing time
points in the laboratory controls.
The lymphoproliferative response to HPV specific fusion proteins were then
assessed by comparison with the control proteins. After 7 days in culture, 7
patients (24 %) and 3 laboratory controls (20 %) responded to HPV- 16 E6 and/or
HPV- 18 E6 and a further patient responded to HPV- 16 E4-/, galactosidase (Table
2). SI were low, ranging from 2-06 to 4 34, and standard errors (SE) were variable
although most were below 25% and any results with SE greater than 30% were
excluded. The difference in responsiveness between patients and laboratory
controls is not significant by the x2 test.
No correlation was found in the patient group between SI and the degree of
dysplasia or presence of koilocytes (data not shown). Similarly there was no
correlation between SI and a past or present history of skin warts in either the
patient or laboratory group. Responses to purified HPV-1 and HPV-2 as antigens
were noted in 6/23 (26%) of patients, a similar proportion to that obtained in
colposcopy patients in our earlier study (15). Two of 11 laboratory personnel also
responded to HPV-2 virion antigens. Proliferative responses to concanavalin A
with SI > 10 were present in all specimens and both negative and positive
responders to HSV-1 were found in both the patient and control groups. In a
separate study we have shown that in patients who are seropositive for HSV, the
SI is always greater than 3; those with recrudescences had a median 51 of 5-7
outwith the time of an attack rising to a median value of 10-6 in the weeks
following the lesion, while those without recrudescences had a median SI of 4 9
(23). These results lend weight to the specificity of the responses obtained with
HPV fusion proteins.
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Table 2. Patients with CIN and laboratory personnel with positive
lymphoproliferative responses to fusion proteins of HPV-16/18 E6 and HPV-16 E4
Lyrnphoproliferative
response to
Control
protein HPV protein
Patient Histological Days in
Antigen number findings culture x cpm S.E. x cpm S.E. SI
HPV-16 E6 P12 N K- 7 224 17 581 88 260
P31 C(IN I. K+ 7 3087 748 7558 835 2-45
P43 CIN II, K+ 7 1343 463 2911 637 2 17
P44 CaCx 7 440 45 958 82 2-18
P48 CUN II, K+ 7 503 65 1146 266 2-28
C5 7 313 36 694 114 2-22
HPV-18 E6 P36 N, K- 7 316 45 1373 366 434
P43 CIN II, K+ 7 1343 463 3846 728 2-86
P45 CIN III K+ 7 1074 275 2215 186 2 06
C2 7 240 46 656 89 2-73
C5 5 350 86 928 58 2-65
C5 7 313 36 765 193 2-44
C7 - 5 261 31 831 118 3 18
HPV-16 E4 P36 N. K- 5 251 14 600 60 2 39
7 527 155 1199 :347 2-27
P, patient; C, laboratory personnel; K+, koilocytes reported; K-, no koilocytes reported;
N, normal; CIN I, II, III, grade of cervical intraepithelial neoplasia; CaCx, carcinoma of the
cervix.
DISCUSSION
Positive but small proliferative responses were observed in 8/29 patients with
CIN and 3/15 apparently healthy laboratory staff to HPV-16 E6 or HPV-18 E6
fusion proteins when examined 7 days after stimulation of peripheral blood
lymphocytes in vitro. The E6 gene has been shown to be involved in BPV cell
transformation (24, 25) and the major transcripts in cervical carcinoma cell lines
and in biopsies of cervical carcinoma are from the E6-E7 region of viral DNA (16,
26). Protein products of E6 and E7 have been found in cervical tumours and in
CaSki and SiHa cell lines which contain HPV-16 DNA and in HeLa cells which
contain HPV-18 DNA (18, 19, 27), although they are not always detected (28, 29).
Recent work suggests that the 20 kDa E7 protein is abundant but has a half-life
of about 1 h (27), while the 16 5 kDa E6 polypeptide may be expressed only at
very low levels (19). Although such investigations have been limited to
transformed cell lines and a few malignant biopsies, it may be that expression is
equally low in cervical HPV infection with or without associated dysplasia. This
would explain why immune responsiveness to E6 proteins was rare and weak.
Responses to E7 proteins may yield more conclusive results.
While the protein product of E4 is abundantly expressed in HPV-1 warts (30,
31) and appears to be associated with virion release by altering the keratin
skeleton (32, 33), its significance in other HPV infections is unknown. A 10 kDa
21 -2
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E4 protein was reported to be produced in CaSki cells (18). However, little
evidence was found in the current study for immune responsiveness to HPV-16
E4. The presence of fl-galactosidase gene in the fusion protein induced proliferation
in three patients and two control subjects, but only one patient (P36, Table 2)
responded specifically to HPV-16 E4 after 5 and 7 days in culture. It is essential
to use highly purified fusion proteins in investigations of the cellular immune
response to HPV products if specific results are to be obtained.
No correlation was noted between lymphoproliferative responses to any of the
fusion proteins and the degree of dysplasia or the presence of koilocytes. In
addition, there was no correlation with a past or present history of skin warts. This
is in contrast to the results we obtained using purified disrupted HPV- 1 or HPV-
2 as antigens in a similar LPA where a correlation was found between a positive
response and a history of skin warts, but not with CIN or koilocytosis (15). It is
thus crucial to use the correct viral antigens in testing CMI in wart infections
caused by different HPV types and it seems likely that the immune response
generated by these types may vary.
In those people who had positive responses to E6 proteins, it would be
interesting to see which T-cell subset had been stimulated. It is possible that some
of the HPV types found in the cervix may induce a preferential T suppressor
response depending on the interaction of the virus with the local antigen
presenting cells. It is interesting to speculate further whether the low responses
may be due to the very low production of any HPV-specific antigen to which the
immune system could respond, to the sequestration of HPV antigens in the upper
layers of the epidermis away from immune effector cells or perhaps to a virally-
induced lack of contact of the virus with antigen presenting cells in the cervix.
This latter suggestion is supported by increasing evidence that Langerhans cells,
the major antigen presenting cells of the skin, are depleted from areas of HPV
infection as well as surrounding areas (34, 35).
The occurrence of positive responses to HPV- 16/18 in apparently normal
women as well as in patients with CIN is not unexpected. It has been shown
increasingly in the last few years that HPV DNA can be detected in normal
cervices (summarized in reference 36) particularly when sensitive methods such as
the polymerase chain reaction (36, 37) are used. It would seem likely that certain
HPV types can persist for long periods while generating minimal detectable
immune response, until some additional factor(s) upsets the balance and enables
clinically evident lesions to develop. Tests of immune responsiveness of peripheral
cells may be unimportant in what is essentially a confined local infection.
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